A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
about
Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopramDesvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.Methodologies used in cost-effectiveness models for evaluating treatments in major depressive disorder: a systematic reviewA critical review of model-based economic studies of depression: modelling techniques, model structure and data sources.A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care.Economic evaluation of agomelatine relative to other antidepressants for treatment of major depressive disorders in Greece.Cost-Effectiveness of Capsaicin 8% Patch Compared with Pregabalin for the Treatment of Patients with Peripheral Neuropathic Pain in Scotland.Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study.Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*D.Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy.Paroxetine: current status in psychiatry.Practice nurse involvement in primary care depression management: an observational cost-effectiveness analysisPotential of St John's Wort for the treatment of depression: the economic perspective.Do productivity costs matter?: the impact of including productivity costs on the incremental costs of interventions targeted at depressive disorders.The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.The Clinical and Cost Effectiveness of Vortioxetine for the Treatment of a Major Depressive Episode in Patients With Failed Prior Antidepressant Therapy: A Critique of the Evidence.Cognitive Behavioral Insomnia Therapy for Those With Insomnia and Depression: A Randomized Controlled Clinical Trial.Efficacy, effectiveness and efficiency of escitalopram in the treatment of major depressive and anxiety disorders.A proposed model for economic evaluations of major depressive disorder.Cost of adverse drug reactions in a South Indian tertiary care teaching hospital.Amisulpride-induced dystonia.Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review.Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders.Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.
P2860
Q33932339-D91C4569-1F95-43C9-BA40-06C53F7F4C07Q33973909-65C2B269-04AE-43B0-B08A-BB26577F7C04Q34148218-9CE82DAD-1E3C-499A-8A0F-7A648C7285F0Q34214236-7A2C0C33-A4EF-4AF5-B63B-A1D0F39C36C4Q34622235-B38D8BEB-8030-42FB-BA6F-CA7AB2848EA2Q34714511-250B8224-F86E-41EF-9321-23AB4C2A8394Q35959802-11445403-ACEB-49D2-9BAF-A328122D0430Q36160446-E853B876-A3F7-40BD-87F3-A2DB54272FA1Q36572744-9A00CB2F-4235-405A-90D3-5F6E4ABCC5B0Q36603437-5E27E0DC-1A29-4833-87D8-E82DD543A4C4Q36730643-19E9163F-0D89-4415-8167-7CEB3818D42AQ37501016-F59838E3-C087-4AF1-BA8A-26968AD17DEDQ37803219-46EF6F37-CD4E-475C-90B3-454C7CA429BEQ37872289-EEB16E2E-EBA3-4B7C-95E2-1234E5CA7603Q38167693-F536374B-09F4-4930-B990-1290F0DB5AFAQ38862355-80C3D1AD-E6D8-4831-BA89-6A1C3DEAED1CQ40443965-2372378B-64C1-42FE-83E7-4170B3A13616Q43042829-0C5411A6-3DBB-4863-8BDA-63701E7A4B49Q44649934-85A1FF22-B82F-4FA4-B951-777AC2D629D1Q44970881-589A79E4-7063-4756-90FE-5F5518768E98Q46574251-A9DCF4D7-5ECE-476C-A91C-4D7FA86824D6Q47117818-35C18C18-3681-424A-A16F-8FE0F6FC4228Q48038510-CC18FE85-6008-4E59-BAF1-7639F69A783DQ48069160-A2F18D38-A8EA-4B0B-BB7B-4B7307090F6DQ48868283-BCE144BF-5532-4225-8482-693818D34060Q48890531-CE9BA401-F588-4AD3-B1CE-FAD381CBC381
P2860
A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
A comparison of the direct cos ...... ciated adverse drug reactions.
@ast
A comparison of the direct cos ...... ciated adverse drug reactions.
@en
type
label
A comparison of the direct cos ...... ciated adverse drug reactions.
@ast
A comparison of the direct cos ...... ciated adverse drug reactions.
@en
prefLabel
A comparison of the direct cos ...... ciated adverse drug reactions.
@ast
A comparison of the direct cos ...... ciated adverse drug reactions.
@en
P2093
P1433
P1476
A comparison of the direct cos ...... ociated adverse drug reactions
@en
P2093
Holly M MacFall
Patrick W Sullivan
Robert Valuck
P304
P356
10.2165/00023210-200418130-00006
P577
2004-01-01T00:00:00Z
P6179
1015422068